logo
[breadcrumb_custom]

Tag: (BIOR)

Finance

BIOR’s Stock Market Pendulum: Swinging Between Gains and Losses

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -55.59%.However, over the last six months, we can see a stronger performance of -66.69%. Over the last 30 days, the price of BIOR has leaped by -49.62%. And in the last five days, it has fallen by -14.95%. Biora Therapeutics Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $6.70 on 06/09/23 and a low of $0.61 for the same time frame

Industry

BIOR’s Stock Journey: What Investors Need to Know About Biora Therapeutics Inc’s Performance

Biora Therapeutics Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $6.70 on 06/09/23, and the lowest price during that time was $0.76, recorded on 04/01/24. 52-week price history of BIOR Stock A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Biora Therapeutics Inc’s current trading price is -89.03% away from its 52-week high, while its distance from the 52-week low is -2.74%. The stock’s price range during this period has fluctuated between $0.76 and $6.70. Shares of the company, which operates

Finance

Biora Therapeutics Inc (BIOR) Stock: A Year of Decreases and Increases

Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Biora Therapeutics Inc’s current trading price is -82.54% away from its 52-week high, while its distance from the 52-week low is 54.76%. The stock’s price range during this period has varied between $0.76 and $6.70. The company, active in the Healthcare sector, saw a trading volume of around 0.6 million for the day, considerably higher average daily volume of 0.39 million observed over the last three months. In terms of market performance, Biora Therapeutics Inc